Search Results - "Daunt, Paula"

The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing by Jones, Clifford D., Andrews, David M., Barker, Andrew J., Blades, Kevin, Daunt, Paula, East, Simon, Geh, Catherine, Graham, Mark A., Johnson, Keith M., Loddick, Sarah A., McFarland, Heather M., McGregor, Alexandra, Moss, Louise, Rudge, David A., Simpson, Peter B., Swain, Michael L., Tam, Kin Y., Tucker, Julie A., Walker, Mike

“…Describes the optimisation of an imidazole amide series, leading to the identification of ( S)- 15b (AZD5597) as a candidate for further development. The…”
Get full text

Clinical experience with polygenic risk score in subjects with early cognitive concerns by Sauer, Justin, Ballard, Clive, Gibson, Alex, Daunt, Paula, Pither, Richard

“…Background There is mounting evidence that lifestyle interventions and behavioural changes play a significant role in maintaining cognition and function, as…”
Get full text

Age-dependent effect of APOE and polygenic component on Alzheimer's disease by Bellou, Eftychia, Baker, Emily, Leonenko, Ganna, Bracher-Smith, Matthew, Daunt, Paula, Menzies, Georgina, Williams, Julie, Escott-Price, Valentina

“…Alzheimer's disease (AD) is a devastating neurodegenerative condition with significant genetic heritability. Several genes have been implicated in the onset of…”
Get full text

A polygenic risk score (PRS) predicts cognitive decline in the APOE3 population in an early Alzheimer’s disease clinical trial cohort by Vasanthakumar, Aparna, Gao, Qian, Daunt, Paula, Flint, Simon, Gibson, Alex, Florian, Hana, Waring, Jeffrey

“…Background Alzheimer’s disease (AD) is one of the most common forms of dementia globally and is defined by accumulation of extracellular amyloid plaques and…”
Get full text

The Relationship between Polygenic Risk Scores, Biomarker Status and Clinical Progression in Longitudinal Observational Cohorts. (4115) by Daunt, Paula, Davidson, Greg, Gibson, Alex, Vasiljevic, Eva, Oshota, Olusegun, Engelman, Corinne, Johnson, Sterling, Pither, Richard

“…Abstract only…”
Get full text

Evaluation of performance of genoSCORETM for predicting onset of Alzheimer’s disease in a Japanese population by Gao, Qian, Daunt, Paula, Kikuchi, Masataka, Miyashita, Akinori, Ozaki, Kouichi, Niida, Shumpei, Iwatsubo, Takeshi, Ikeuchi, Takeshi, Gibson, Alex, Pither, Richard

“…Background The development of diagnostic tools to identify disease risk is critical to enable selection of suitable individuals for inclusion in clinical…”
Get full text

Evaluation of performance of genoSCORE TM for predicting onset of Alzheimer’s disease in a Japanese population by Gao, Qian, Daunt, Paula, Kikuchi, Masataka, Miyashita, Akinori, Ozaki, Kouichi, Niida, Shumpei, Iwatsubo, Takeshi, Ikeuchi, Takeshi, Gibson, Alex, Pither, Richard

“…Abstract Background The development of diagnostic tools to identify disease risk is critical to enable selection of suitable individuals for inclusion in…”
Get full text

Polygenic risk scores predict cognitive impairment as measured by the Preclinical Alzheimer Cognitive Composite (PACC) score in the ADNI cohort by Pither, Richard, Daunt, Paula, Davidson, Greg, Gibson, Alex, Gao, Qian, Oshota, Olusegun

“…Background The development of diagnostic tools to identify disease risk is critical to enable selection of suitable individuals for inclusion in clinical…”
Get full text

Identifying individuals with mild cognitive impairment who are at higher genetic risk of further substantial cognitive decline due to Alzheimer's disease: Biomarkers (non‐neuroimaging)/Use in clinical trial design and evaluation by Pither, Richard, Daunt, Paula, Davidson, Greg, Gibson, Alex, Hill, Anthony, Oshota, Olusegun

“…Abstract Background The development of tools to identify disease risk is critical to enable selection of suitable individuals for inclusion in clinical trials…”
Get full text

Identifying individuals with mild cognitive impairment who are at higher genetic risk of further substantial cognitive decline due to Alzheimer's disease by Pither, Richard, Daunt, Paula, Davidson, Greg, Gibson, Alex, Hill, Anthony, Oshota, Olusegun

“…Background The development of tools to identify disease risk is critical to enable selection of suitable individuals for inclusion in clinical trials and…”
Get full text

P1‐028: POLYGENIC RISK SCORE DISTRIBUTIONS OF ALZHEIMER'S DISEASE WITHIN DIFFERENT POPULATIONS by Bellou, Eftychia, Leonenko, Ganna, Daunt, Paula, Oshota, Olusegun, Gibson, Alex, Pither, Richard, Sims, Rebecca, Williams, Julie, Escott-Price, Valentina

Get full text

POLYGENIC RISK SCORE DISTRIBUTIONS OF ALZHEIMER’S DISEASE WITHIN DIFFERENT POPULATIONS by Bellou, Eftychia, Leonenko, Ganna, Daunt, Paula, Oshota, Olusegun, Gibson, Alex, Pither, Richard, Sims, Rebecca, Williams, Julie, Escott-Price, Valentina

Get full text

STRATIFICATION OF INDIVIDUALS FOR PET AMYLOID POSITIVITY AND ALZHEIMER’S DISEASE RISK USING POLYGENIC RISK SCORE ANALYSIS: NEW OPPORTUNITIES FOR CLINICAL TRIAL DESIGN by Pither, Richard, Shoai, Maryam, Escott-Price, Valentina, Laws, Simon M., Hampel, Harald, Oshoto, Olusegun, Daunt, Paula, Gibson, Alex, Banks, Kevin, Nagy, Zsuzsanna, Hardy, John

Get full text

P3‐248: STRATIFICATION OF INDIVIDUALS FOR PET AMYLOID POSITIVITY AND ALZHEIMER'S DISEASE RISK USING POLYGENIC RISK SCORE ANALYSIS: NEW OPPORTUNITIES FOR CLINICAL TRIAL DESIGN by Pither, Richard, Shoai, Maryam, Escott-Price, Valentina, Laws, Simon M., Hampel, Harald, Oshoto, Olusegun, Daunt, Paula, Gibson, Alex, Banks, Kevin, Nagy, Zsuzsanna, Hardy, John

Get full text

A STREAMLINED INTEGRATED PROCESS TO PREDICT GENETIC RISK OF ALZHEIMER’S DISEASE by Daunt, Paula, Banks, Kevin, Davidson, Greg, Gibson, Alex, Hill, Anthony, Oshota, Olusegun, Bellou, Eftychia, Escott-Price, Valentina, Leonenko, Ganna, Sims, Rebecca, Williams, Julie, Hardy, John, Shoai, Maryam, Nagy, Zsuzsanna, Pither, Richard

Get full text

P4‐202: A STREAMLINED INTEGRATED PROCESS TO PREDICT GENETIC RISK OF ALZHEIMER'S DISEASE by Daunt, Paula, Banks, Kevin, Davidson, Greg, Gibson, Alex, Hill, Anthony, Oshota, Olusegun, Bellou, Eftychia, Escott-Price, Valentina, Leonenko, Ganna, Sims, Rebecca, Williams, Julie, Hardy, John, Shoai, Maryam, Nagy, Zsuzsanna, Pither, Richard

Get full text

Abstract 3676: Influence of early toxicology assessment on the selection of azd9291 by Anderton, Mark J., Ward, Richard A., Daunt, Paula, Galer, Anne, Cross, Darren A. E., Marks, Louise, Finlay, M. Raymond V.

“…Abstract Discovery toxicology is the concept of evaluating the safety of molecules early in the drug development process when there is chemical scope to refine…”
Get full text

Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma by Cross, Darren, Ashton, Sue, Nebhan, Caroline, Eberlein, Cath, Finlay, M. Raymond V., Hughes, Gareth, Jacobs, Vivien, Mellor, Martine, Red Brewer, Monica, Meador, Catherine, Orme, Jonathon, Spitzler, Paula, Powell, Steve, Rahi, Amar, Taylor, Paula, Ward, Richard A., Daunt, Paula, Galer, Anne, Klinowska, Teresa, Richmond, Graham, Pao, William

“…Abstract The first generation EGFR TKIs gefitinib and erlotinib provide significant clinical benefit in patients with advanced lung adenocarcinoma harbouring…”
Get full text